
Oncology NEWS International
- Oncology NEWS International Vol 4 No 7
- Volume 4
- Issue 7
Medco Research, Inc. and Repligen Corporation Have Agreed to Merge
CAMBRIDGE, Mass--Repligen Corporation and Medco Research, Inc. (Research Triangle Park, NC) have agreed to merge their two companies. The resulting company's product portfolio will serve three primary markets: cardiovascular disease, oncology, and immunology.
CAMBRIDGE, Mass--Repligen Corporation and Medco Research, Inc.(Research Triangle Park, NC) have agreed to merge their two companies.The resulting company's product portfolio will serve three primarymarkets: cardiovascular disease, oncology, and immunology.
Medco's products include ATP, an adenosine product under investigationas an antitumor agent and to prevent the weight loss and wastingassociated with chemotherapy and radiation. Among Repligen's cancerdrugs under development is recombinant platelet factor 4 (rPF4),which has shown potential as an antiangiogenesis agent.
Articles in this issue
almost 31 years ago
ODAC Recommends Accelerated FDA Approval of Ethyol for Cytoprotectionalmost 31 years ago
House Panel Holds Hearing on Self-Referralalmost 31 years ago
Health-Related Legislationalmost 31 years ago
Mitoguazone Appears Promising in HIV-Associated Refractory NHLalmost 31 years ago
Responses to Anti-HER2 MoAb Seenalmost 31 years ago
NCI Committed to Increasing Minority Participation in Clinical Trialsalmost 31 years ago
MoAb May Improve Detection of Colon And Rectal Canceralmost 31 years ago
Zeneca Files NDA for Arimidexalmost 31 years ago
Cord Blood is Used as Source of Stem Cells for Pediatric TransplantationNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content



















































